-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 23, Hengrui Medicine announced that it had received the "Notice of Drug Clinical Trial Approval" issued by the State Drug Administration for SHR7280 tablets, and will conduct clinical trials in the near future
SHR7280 is an oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, which can block the binding of endogenous GnRH to GnRH receptors, inhibiting the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) Synthesis and release of gonadal hormones, reducing levels of sex hormones such as testosterone and estradiol